Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. It is characterized by a progressive loss of function and can lead to end-stage renal disease (ESRD), necessitating dialysis. The most common causes of CKD are diabetes and hypertension. As the prevalence of hypertension and diabetes continues to increase, so too does the prevalence of CKD and the cost to national healthcare systems for treating these patients. Thus, the commercial opportunity for drugs with proven efficacy in delaying the progression of this condition and/or treating its symptoms is considerable.
Questions Answered in This Report:
- More than 70 million people in the major pharmaceutical markets under study are living with CKD, a figure that will increase to 79 million over the next ten years due to demographic changes. What is the prevalence of CKD in the seven major markets? How are diagnosis and drug-treatment rates likely to change over the 2014-2024 forecast period?
- Because of the lack of disease-modifying agents for CKD, treatment of patients is aimed at minimizing the symptoms and complications arising from progressively diminished kidney function. The most common complications are renal anemia, hyperphosphatemia, and SHPT. How are CKD and its complications currently treated? How does treatment vary in the seven major markets discussed in this report, and how is it likely to change in each market in the next ten years? What reimbursement restrictions are imposed in each market?
- The late-stage pipeline for CKD therapies has several therapies with substantial sales potential. What are the most promising therapies in development for CKD and its complications? With which current agents will these drugs compete, and how will they differentiate themselves from the competition? ?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 23 country-specific interviews with thought-leading experts in kidney disease.
Population segments in market forecast: stages 3, 4, 5 nondialysis, and 5 dialysis.
Emerging therapies: Phase II: 8 drugs; Phase III: 3 drugs; preregistration: 4 drugs.
Caitlin Koris, M.S.Ph.
Catherine Vasilakis-Scaramozza, Ph.D., M.P.H.
Seth Kuranz, M.P.H.